We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subc... Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Show more
Ask ADVFN Intelligence (AI)
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the...
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly...
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.03 | 5.03597122302 | 40.31 | 42.95 | 39 | 407721 | 40.22732563 | CS |
| 4 | -3.53 | -7.6956616525 | 45.87 | 50.56 | 36.48 | 541112 | 41.1633061 | CS |
| 12 | -16.59 | -28.1520447989 | 58.93 | 63.5 | 36.48 | 525401 | 45.68839953 | CS |
| 26 | -7.8 | -15.5564419625 | 50.14 | 63.5 | 36.48 | 449818 | 48.62016157 | CS |
| 52 | 4.91 | 13.1178199305 | 37.43 | 72.29 | 32.78 | 509453 | 50.67914278 | CS |
| 156 | 20.84 | 96.9302325581 | 21.5 | 72.29 | 14.19 | 445396 | 43.28463749 | CS |
| 260 | 20.84 | 96.9302325581 | 21.5 | 72.29 | 14.19 | 445396 | 43.28463749 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
